A new ERA for global Dermatology

10 - 15 June 2019

remain to congress inauguration



The WCD 2019 Scientific Committee recognizes that the results of some exciting basic or clinical research may not be available by the general abstract submission deadline. Hence, WCD 2019 offers a call for Late-Breaking Abstract submissions for abstracts that highlight truly novel and substantive scientific findings. The goal is to enrich the WCD annual meeting with innovative studies that are completed after the general abstract submission deadline. Please note that Late-Breaking Abstracts are not intended to offer a second deadline for regular abstract submission. Deadline for online Late-Breaking Abstract submission is February 28, 2019.

The presenting author of a Late-Breaking Abstract MUST REGISTER FOR THE WCD BY 30 APRIL, 2019 before the abstract can officially be accepted for inclusion in the final scientific program and official Program Book.

Late Breaking abstract Opening Late Breaking abstract closing Late Breaking Abstract Acceptance Notification
1 February, 2019 28 February, 2019 Starting from 1 April, 2019


  • Authors are required to indicate their preference for either ORAL or POSTER presentation by checking the appropriate box on the submission web page. The WCD Free Communications Committee will make the final decision on the format of presentation (i.e. oral or poster). Few selected posters will be scheduled for short oral presentations.
  • Acceptance or rejection of abstracts will be based on rankings given by a peer review of experts in the associated topic/category. Results of the selection process will be sent via e-mail to the corresponding author. The Committee decision is final and cannot be appealed.
  • Abstracts cannot be identical to any abstract that has previously been presented at a major international meeting prior to the WCD 2019. An update to prior study is acceptable.
  • Instructions on the preparation of posters and information about projection facilities will be included with the notification of acceptance.
  • Submission of an abstract indicates:
    1. that the author(s) agree to comply with the abstract submission and presentation rules;
    2. that the presentation is based on scientific and/or clinical methods that are ethical and valid;
    3. that all authors have contributed to and approve the abstract and its entire contents.
  • All accepted abstracts will be published electronically on digital media and on the WCD 2019 website, and distributed to all delegates.
  • Accepted abstracts are official communications of the Congress. The presenting author agrees to register, to attend the Congress, and to present the abstract as scheduled by the WCD.
  • The evaluation and scoring of the abstract (acceptance as poster or as oral communication, or rejection) will be made according to a number of criteria, including:
    1. Scholarly and/or research validity
    2. Educational value
    3. Clarity of presentation
    4. Potential impact on global dermatology


(Please refer to the Abstract Template for specific guidance on formatting)

  1. Abstracts must be written and presented in English. Abstracts that are not written in understandable English will be rejected and/or returned to the author(s) for revision.
  2. Abstract must be uploaded in WORD format (.doc; .docx)
  3. Title, author’s names, author’s affiliation, presenting author must be provided by filling the online form
    • Title: Use a concise descriptive title that indicates the content of the abstract. Please minimize the use of abbreviations in the title. Commercial trade names for drugs, devices, products, and services may NOT be used in the title.
    • Author: The initial letter of the name(s) and the full surname for each author must be provided. Do not include degrees or titles.
    • Affiliations: Each author should be listed by department, institution, city, and country.
  4. The body of the abstract text should not exceed 300 WORDS. The online submission program will automatically not allow submissions that do not fit this requirement. Symbols including superscripts and subscripts can be entered in the online system.
  5. The body of the abstract text must be formatted with the following sub-headings as appropriate. Each sub-heading should be formatted in bold text, begin on a new line, and followed by a colon and space (:). The text for each sub-section should begin immediately after the colon and space (see sample abstract below).

For clinical or investigative studies:

  • Introduction:
  • Objective:
  • Materials and Methods:
  • Results:
  • Conclusions:

For case reports or case series:

  • Background:
  • Observation:
  • Key message:

It is NOT satisfactory to simply state that “The results will be discussed.” Only common and standard abbreviations may be used without definition.


Check spelling and grammar carefully. Direct reproduction from your electronically submitted abstract text means that any errors in spelling, grammar or scientific data will be reproduced as submitted.

Drugs, devices, products, and services should be identified by generic name only within the abstract. The use of commercial drug names, brands and registered trademarks are strictly prohibited. No mention of pharmaceutical company names should be included in the abstract.

Data must be given in units (International metric system is preferred) that are generally accepted in scientific publications.

All co-authors must agree with the submitted results and conclusions, and consent to being listed as authors.

Work involving humans or animals, or material derived from them must have been approved by an institutional ethics committee.


For reviewing and scheduling purposes, abstracts will be classified into thematic areas. Please indicate on the submission webpage the appropriate topic classifications to which your abstract belongs. Only 1 thematic category may be chosen. The WCD Free Communications Committee will attempt to respect the authors’ choice regarding their self-selection to a specific topic, but reserves the right to change the allocation in order to achieve a well-balanced scientific program.

  • Acne, rosacea, and related disorders (including hidradenitis suppurativa)
  • Adverse drug reactions, including SJS, TEN
  • Aesthetic and cosmetic dermatology (lasers separate category)
  • Art in dermatology
  • Atopic eczema/dermatitis
  • Autoimmune bullous diseases
  • Autoimmune connective tissue diseases
  • Contact dermatitis and occupational dermatoses
  • Dermatological surgery
  • Dermatopathology
  • Dermoscopy and skin imaging
  • Epidemiology
  • Ethics
  • Gender dermatology
  • Genetics and Genodermatoses
  • Global Skin Health
  • Haemangiomas and vascular malformations
  • Hair disorders
  • History of Dermatology
  • Humanitarian dermatology/migrant health
  • Hyperhidrosis
  • Infectious diseases (bacterial, fungal, viral, parasitic, infestations)
  • Inflammatory skin diseases (other than atopic dermatitis & psoriasis)
  • Lasers
  • LGBT Health
  • Medical therapies and pharmacology
  • Melanoma and melanocytic naevi
  • Mucosal diseases (oral, anogenital), external eye disease
  • Nail disorders
  • Paediatric dermatology
  • Photobiology and Photoprotection
  • Phototherapy, photodynamic therapy
  • Pigmentation
  • Pruritus
  • Psoriasis
  • Psychodermatology
  • Quality of Life, Quality of Care, and Patient Safety
  • Sexually transmitted infections, HIV/AIDS
  • Skin cancer (other than melanoma)
  • Skin manifestations of internal disease
  • Teledermatology
  • Tropical dermatology
  • Urticaria, angioedema
  • Vascular disease, vasculitis
  • Wound healing


Online Late-Breaking Abstract Submission will be available on the Congress website until 28 February, 2019

Please follow the instructions detailed on the website. Your abstract submission will be acknowledged automatically by email, but this confirmation does not constitute official acceptance for presentation.


Submitted Late-Breaking Abstract can be modified until 28 February, 2019 (abstract submission deadline). Please remove the abstract previously submitted and upload the new document.

Authors who wish to withdraw their abstract must send a written request to: wcd2019abstract@thetriumph.com.


Authors will be notified starting from 31 March, 2019 as to the acceptance status of their submissions. This includes the assignment of session category and presentation format (oral or poster). Detailed instructions regarding requirements and instructions for oral and poster presentations will also be provided at that time.

If your Late-Breaking Abstract is accepted, you must register no later than 30 April, 2019. Unless you register by that date, your abstract will not be included in any WCD print or online publications or the official program book.

For more information please contact:

WCD 2019 Secretariat




Registration is now open

Registration is now open

Join WCD 2019 and register now to benefit of special rates!

Click here to register

Hotel rooms are being held for participants at reduced rates.

Reserve your hotel accommodation

Abstract submission

Late-breaking abstract

To enrich the WCD annual meeting with innovative studies that are completed after the general abstract submission deadline, WCD 2019 offers a call for Late-Breaking Abstract submissions for abstracts that highlight truly novel and substantive scientific findings.


Abstract submission

Discounted flight tickets

Lufthansa Group Partner Airlines offer a comprehensive global route network linking major cities around the world. Lufthansa Group Partner Airlines offer special prices and conditions to WCD2019 participants.

Book your discounted flight

In order to provide you with a better browsing experience, this site or the third-party tools used by it employ technical, analytical and profiling cookies from third parties. By closing this banner, scrolling through this page, clicking on any of its elements or otherwise continuing to browse this site, you authorize such use of the cookies. If you want to know more or to deny authorization to all or some of the cookies, please read the cookie policy.OK